dabrafenib + LTT462 + tislelizumab

**dabrafenib + LTT462 + tislelizumab** is an experimental triplet combination therapy evaluated in early-phase oncology trials. Dabrafenib is a small molecule inhibitor of BRAF kinase, approved for use in several cancers with BRAF V600 mutations. LTT462 is a small molecule inhibitor that targets ERK signaling downstream of BRAF, under investigation for treating solid tumors in patients with MAPK pathway alterations. Tislelizumab is a humanized IgG4 monoclonal antibody targeting the programmed cell death protein 1 (PD-1), serving as an immune checkpoint inhibitor to enhance antitumor immune responses. The triplet is being studied primarily for tumors with aberrant MAPK/RAF pathway activity, including metastatic solid tumors and possibly colorectal cancer, aiming to combine targeted inhibition of tumor proliferation (dabrafenib, LTT462) with immune-mediated antitumor activity (tislelizumab)[3][7][5].

Brand names

Tafinlar (dabrafenib)